newsfilter
← Latest News
Business Wire·

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated,